Document Detail


Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
MedLine Citation:
PMID:  19159848     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Drug-eluting stents (DESs) have been shown to decrease restenosis as compared with bare-metal stents. Recently, thiazolidinediones effectively reduced restenosis and the risk of repeat target vessel revascularization. We conducted a study to compare the performance of a DES with that of a bare-metal stent with pioglitazone in patients with Type 2 diabetes mellitus (DM). METHODS: The study was a prospective cohort trial involving 38 Type 2 diabetic patients referred for coronary stenting who were assigned to either the sirolimus-eluting stent (SES) group or the pioglitazone group. Quantitative coronary angiography was performed at study entry and at 6 months of follow-up to evaluate in-stent late luminal loss and the percentage of the luminal diameter and the rate of restenosis. We also analyzed major adverse cardiac events (MACE) at 12 months. RESULTS: There were no significant differences in glycemic control levels or in lipid levels in the two groups at follow up. The insulin and homeostasis model assessment insulin resistance at follow-up were significantly lower in the pioglitazone group than in the SES group. The percentage of restenosis was similar between the SES group and the pioglitazone group. The incidence of MACE at 1 year tended to be lower in the pioglitazone group than in the SES group. CONCLUSIONS: The bare-metal stent with pioglitazone is not inferior to the SES in the present study and is one of therapeutic strategies of percutaneous coronary intervention for patients with DM.
Authors:
Kazuaki Nishio; Meiei Shigemitsu; Yusuke Kodama; Noburu Konno; Takashi Katagiri; Youichi Kobayashi
Related Documents :
8608668 - Restenosis following coronary angioplasty: clinical presentations and therapeutic options.
18606378 - Enhanced level of micronuclei in peripheral blood lymphocytes of patients treated for r...
7634448 - Early and late quantitative angiographic results of vein graft lesions treated by excim...
22499848 - High-resolution versus standard-resolution cardiovascular magnetic resonance myocardial...
729598 - Myoglobinemia after myocardial infarction; influence of renal function.
16969848 - Day case transradial coronary angioplasty: a four-year single-center experience.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Cardiovascular revascularization medicine : including molecular interventions     Volume:  10     ISSN:  1878-0938     ISO Abbreviation:  -     Publication Date:    2009 Jan-Mar
Date Detail:
Created Date:  2009-01-22     Completed Date:  2009-03-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101238551     Medline TA:  Cardiovasc Revasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5-11     Citation Subset:  IM    
Affiliation:
The Third Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan. kazukun@jg7.so-net.ne.jp
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00482183
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects,  instrumentation*
Blood Glucose / drug effects
Cardiovascular Agents / administration & dosage*
Cardiovascular Diseases / etiology,  prevention & control
Coronary Angiography
Coronary Restenosis / etiology,  prevention & control
Coronary Stenosis / complications,  metabolism,  radiography,  therapy*
Diabetes Mellitus, Type 2 / complications,  metabolism,  therapy*
Drug-Eluting Stents*
Female
Humans
Hypoglycemic Agents / therapeutic use*
Insulin / blood
Insulin Resistance
Lipids / blood
Male
Metals*
Middle Aged
Prospective Studies
Prosthesis Design
Sirolimus / administration & dosage*
Stents*
Thiazolidinediones / therapeutic use*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Cardiovascular Agents; 0/Hypoglycemic Agents; 0/Lipids; 0/Metals; 0/Thiazolidinediones; 11061-68-0/Insulin; 111025-46-8/pioglitazone; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The year in cardiothoracic and vascular anesthesia: selected highlights from 2008.
Next Document:  Off-pump coronary artery bypass grafting improves in-hospital mortality in patients with dialysis-de...